Shanghai Shiya Pharmaceutical Technology

Shanghai Shiya Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on addressing significant unmet medical needs in metabolic diseases, respiratory conditions, and autoimmune disorders. Its lead program, SY-001, is a potent URAT1 inhibitor currently in Phase 2 clinical development for hyperuricemia and gout. Additionally, Shiya is advancing SY-005, a THR-beta agonist for NASH, and SY-009, a P2X3 antagonist for chronic cough, through early-stage clinical trials. The company utilizes a robust drug discovery platform centered on medicinal chemistry and structure-based design to build a diverse pipeline of high-potential candidates.